Nevolat (Liraglutide)

Liraglutide mimics the natural incretin hormone GLP‑1. By binding to GLP‑1 receptors on pancreatic beta cells, it enhances insulin secretion only when blood glucose is elevated, suppresses glucagon release, slows gastric emptying, and acts on brain centers to decrease appetite, thereby lowering blood glucose and supporting weight loss.

The dosage of Nevolat is individualized. A qualified prescriber determines the starting dose, titration schedule, and maintenance dose based on the patient’s clinical condition, response, and tolerability. Patients should follow the prescribing information and the healthcare professional’s instructions.

Safety data for liraglutide in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nevolat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and assistance with import documentation.

Nevolat (liraglutide) shares the core GLP‑1 receptor agonist mechanism with drugs such as exenatide and semaglutide, but differs in dosing frequency, molecular size, and duration of action. Liraglutide is typically administered once daily, whereas some alternatives are weekly. Clinical efficacy in glycaemic control and weight loss is comparable, while safety profiles are similar, with nausea being the most common adverse effect.

Nevolat must be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original carton, protect it from light, and do not freeze or shake the vial. If a temporary excursion above 8 °C occurs for less than 24 hours, the product may still be used, but prolonged exposure requires discarding.

Nevolat is given as a subcutaneous injection, usually in the abdomen, thigh, or upper arm. The injection site should be rotated with each dose to reduce local irritation. Patients are instructed to use a sterile, single‑use pen or syringe, follow the prescriber’s titration schedule, and monitor for any injection‑site reactions.

The most serious risks include pancreatitis, gallbladder disease, severe hypoglycemia (especially when combined with insulin or sulfonylureas), acute kidney injury, and, based on animal studies, a potential risk of thyroid C‑cell tumors. Patients should be educated to seek immediate medical attention for persistent abdominal pain, jaundice, or signs of severe hypoglycemia.

Nevolat is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia type 2, or patients who have experienced a severe hypersensitivity reaction to liraglutide or any of its excipients. Caution is also advised for patients with severe renal impairment, acute pancreatitis, or known gallbladder disease.